RBC Capital Maintains 'Sector Perform' Rating on Regeneron: An Analysis
Money

RBC Capital Maintains 'Sector Perform' Rating on Regeneron: An Analysis

authorBy JL Collins
DateJun 28, 2026
Read Time1 min

RBC Capital has upheld its 'Sector Perform' rating for Regeneron Pharmaceuticals, assigning a price target of $707. This rating is given even as the firm notes that AbbVie's recent acquisition of Apogee Therapeutics presents a disadvantage for Regeneron. The acquisition introduces a formidable competitor in the dermatology market, equipped with extensive commercial expertise and a history of successfully marketing key products, potentially challenging Regeneron's offerings.

Simultaneously, Regeneron Pharmaceuticals recently shared a significant update regarding its maftivimab treatment. The World Health Organization's Therapeutics Advisory Group has endorsed maftivimab for prioritized assessment in clinical trials targeting Bundibugyo ebolavirus. Maftivimab, a potent neutralizing antibody found in Inmazeb®, has demonstrated broad-spectrum efficacy against multiple Ebola variants in laboratory settings.

Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for a range of serious medical conditions, including various cancers, ocular diseases, and allergic responses. Their ongoing research and development efforts continue to contribute to advancements in medical science and patient care globally. The company's commitment to tackling complex health challenges underscores its role as a key player in the pharmaceutical industry.

More Articles
Money
Navigating the Tech Market Downturn: Rebalancing Investment Portfolios
Recent market trends show a downturn in major tech stocks like Alphabet, Amazon, and Tesla, alongside a fading enthusiasm for AI stocks. This shift prompts investors to consider rebalancing their portfolios. While immediate drastic changes may not be necessary for well-diversified portfolios, the long-term outlook suggests a potential pivot towards more defensive, value-oriented sectors such as energy, healthcare, utilities, and consumer staples, moving away from aggressive tech growth.
By Chika UwazieJun 28, 2026
Money
Danaher: A Leading Non-Tech Stock with Promising Outlook
Danaher Corporation (DHR) is considered a top non-tech stock by analysts. The company's recent FDA clearance for an opioid-induced respiratory depression detection feature in its Radius VSMﾮ patient monitor highlights its innovation in specialty diagnostics. However, a recent downgrade by Wolfe Research to "Peer Perform" raises questions about its valuation compared to competitors like Thermo Fisher and its strategic direction post-Masimo transaction. Danaher operates across Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.
By Natalie PaceJun 28, 2026
Money
SoFi's AI-Powered Innovation Poised to Boost Growth
SoFi Technologies has introduced SoFi Coach, an AI-driven chat feature designed to provide personalized financial insights. Despite recent stock fluctuations, the company's commitment to product innovation, particularly in AI, is expected to enhance customer experience, foster cross-selling opportunities, and significantly contribute to its already rapid growth trajectory, which saw a 35% increase in customers and 41% rise in adjusted net revenue year-over-year.
By Ramit SethiJun 28, 2026
Money
AMD's MEXT Acquisition: Impact on Memory Market and Competitors
Advanced Micro Devices recently acquired MEXT, a startup specializing in AI-driven software that optimizes NAND flash to function like DRAM. This move aims to significantly reduce memory costs and expand usable memory capacity for AI workloads. While some investors might worry about its implications for companies like Micron and Sandisk, the acquisition's primary focus is on enhancing efficiency for enterprise AI, rather than replacing high-bandwidth memory crucial for large AI models. This strategic acquisition is unlikely to threaten, and may even benefit, memory manufacturers.
By Bola SokunbiJun 28, 2026
Money
Top Economist Warns Against Fed Rate Hikes for 2026
EY-Parthenon's chief economist, Greg Daco, challenges conventional wisdom regarding Federal Reserve interest rate hikes. He argues that current inflationary pressures are supply-driven, not demand-driven, and that further rate increases could harm an already fragile economy. Daco believes the Fed should maintain current rates, as higher energy prices, AI's strain on resources, and stagnant real incomes indicate a supply problem that monetary policy cannot easily resolve.
By T. Harv EkerJun 28, 2026